- /
- Supported exchanges
- / US
- / SGMT.NASDAQ
Sagimet Biosciences Inc. Series A Common Stock (SGMT NASDAQ) stock market data APIs
Sagimet Biosciences Inc. Series A Common Stock Financial Data Overview
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Sagimet Biosciences Inc. Series A Common Stock (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Sagimet Biosciences Inc. Series A Common Stock data using free add-ons & libraries
Get Sagimet Biosciences Inc. Series A Common Stock Fundamental Data
Sagimet Biosciences Inc. Series A Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Sagimet Biosciences Inc. Series A Common Stock Earnings data
What’s included:
- Latest Release: 2025-11-13
- EPS/Forecast: -1.04
Get Sagimet Biosciences Inc. Series A Common Stock End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sagimet Biosciences Inc. Series A Common Stock News
New
Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
CancerVAX, Inc Dr. George Kemble, former AstraZeneca executive, to advise the Company on immunological and viral strategies for its novel cancer treatment platform Lehi, Utah, Jan. 27, 2026 (GLOBE N...
Biotech Veteran and Virologist Joins CancerVax as Senior Scientific Advisor
Lehi, Utah, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lehi, Utah, January 27, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune syst...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.